Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So BCDA had an offering too and it ran !! This didn’t shit
I should have added that if they get FDA approval this will beat Citigroups estimate of $6 BIG TIME.
That looks likely too imo.
Citigroup setting a price target of $6 was an easy tell imo that an offering was near. Their speculation without data to support it was way out there. No one knows the future. The herd simply reacted to that, probably mostly traders, but certainly some investors. Volatility came in and many took advantage.
Results will take this on up big time imo. Longs know to ignore the day to day.
Just my thoughts anyway. This manipulation runs rampant in bio land.
Do not understand the 3.20 at all.
Just screwed investors today big time with that announcement.
This would have run 5-8 bucks today if that was not announced or set at a better price.
$65M @ 3.20. Really? Figured that'd be coming after their $6 target.
https://finance.yahoo.com/news/lexicon-announces-offering-common-stock-130200745.html
Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain
https://ih.advfn.com/stock-market/NASDAQ/lexicon-pharmaceuticals-LXRX/stock-news/83883256/lexicon-pharmaceuticals-receives-fast-track-design
Skimmed a few @ $5 but certainly looking to add again.
Glad i added on the dip!!!
Bring on a deal!
Thanks, looks like this will turn into a nice little money earner.
I have no idea at what price this can end at, FDA meeting in January, is between 10 & 20 realistic if all goes well?
If it keeps going up, I will likely sell off about 20% so I am covered in case of disaster.
* * $LXRX Video Chart 12-08-2020 * *
Link to Video - click here to watch the technical chart video
Lexicon Pharmaceuticals shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $2.1 to $6 per share.
LXRX
when is next month
They are bullish on heart failure drug caused from diabetes...
FDA meeting next month, looks like they have the goods... GLTA
Be nice to know why they raised it. Maybe a PR will be out today. They must know something.
2020-12-08 12:59:00 GMT DJ Lexicon Pharma Price Target Raised to $6.00/Share From $2.10 by Citigroup
Took a few off 2.20, looks like I may have been a bit impatient.
Nice going Guzzi! Added myself last Friday @ 1.60.
Gone up a lot over the last few days and pre-market looks good too.
Glad I came in at 1.5 last week.
Agree. If this reversal sticks we could see this test the major resistance levels of $2 and possibly $3.
Charts are looking pretty good.
LXRX daily
LXRX reversal Notice the inverted head & shoulders. Big time bullish signal.
All imo of course.
A little more momentum and the walls will be coming down!
Happy Friday!
This market is NUTS!!!
Interesting ...
Kinda looks like this could see another wave up. Gap hasn't even filled yet.
LXRX 1.56
What's next for LXRX after the positive SOLOIST and SCORED peer review recently?They are in Phase 3 for Sotagliflozin,right?So,is an approval the next anticipated step?Read that they are meeting with the FDA in Jan 2021,what is that meeting related to?Thanks.
* * $LXRX Video Chart 11-17-2020 * *
Link to Video - click here to watch the technical chart video
Same here, the news and the volume are both good... GLTA
1.80's looks good for me to come out and play and not look back here again all day.
I thought this would have popped to at least $3.00 today
My mistake
yep that's an easy reachable target with this Phase 3 news.
Holding the rest of my shares for $5+.
Heart Attack and Stroke is the most common ailment, the MARKET for LXRX is HUGE!
LXRX BOOM $2.20
LXRX $2.04 Phase 3/ Peer Reviewed, Stroke/ Heart Attack is a HUGE Market! IMO
Nothing new in bioland that's for sure. Excellent news that makes LXRX even more attractive.
Thanks for posting, haven't had a chance to check filings yet this morning.
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies
http://www.lexpharma.com/media-center/news/760-results-from-soloist-and-scored-outcomes-studies-presented-at-late-breaking-science-session-of-american-heart-association-scientific-sessions-and-published-in-the-new-england-journal-of-medicine
Excellent! Peer review!
https://finance.yahoo.com/news/results-soloist-scored-outcomes-studies-030200976.html
Skimmed a few in PM.
I just can't help myself sometimes. It's been beaten into my brain to take green when it's screaming at me!
GLTA
DILUTION > SHELF PLACEMENT > SEC 424B5 >LXRX has entered into an Open Market Sale AgreementSM (the “sales agreement”) with Jefferies LLC (“Jefferies”) relating to the shares of our common stock, par value $0.001 per share (“common stock”), offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offer and sell our common stock having an aggregate sales price of up to $50,000,000 from time to time through Jefferies acting as our sales agent.
Our common stock trades on the Nasdaq under the symbol “LXRX.” On October 29, 2020, the last reported sale price of our common stock on the Nasdaq was $1.16 per share.
Sales of common stock, if any, under this prospectus supplement will be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Jefferies is not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Jefferies and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The compensation to Jefferies for sales of common stock sold pursuant to the sales agreement will be at an amount equal to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement. The net proceeds from any sales under this prospectus supplement will be used as described under “Use of Proceeds” in this prospectus supplement. In connection with the sale of the common stock on our behalf, the Jefferies will be deemed to be “underwriter” within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. See “Plan of Distribution” on page S-7 of this prospectus supplement for additional information concerning the compensation to be paid to Jefferies.
Clearing their debt obviously cost shareholders plenty!!!
Still, opportunity? I took a few here. 1.12/1.13.
Took a huge loss on this one today
GLTA that remain
Followers
|
56
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
781
|
Created
|
02/27/05
|
Type
|
Free
|
Moderators |
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies
THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.
In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.
The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.
“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |